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Follow-upa b s t r a c t
Squamous cell carcinoma of the anus (SCCA) is a rare cancer but its incidence is increasing throughout the
world, and is particularly high in the human immunodeﬁciency virus positive (HIV+) population. A mul-
tidisciplinary approach is mandatory (involving radiation therapists, medical oncologists, surgeons, radi-
ologists and pathologists). SCCA usually spreads in a loco-regional manner within and outside the anal
canal. Lymph node involvement at diagnosis is observed in 30–40% of cases while systemic spread is
uncommon with distant extrapelvic metastases recorded in 5–8% at onset, and rates of metastatic
progression after primary treatment between 10% and 20%. SCCA is strongly associated with human
papilloma virus (HPV, types 16–18) infection. The primary aim of treatment is to achieve cure with
loco-regional control and preservation of anal function, with the best possible quality of life. Treatment
dramatically differs from adenocarcinomas of the lower rectum. Combinations of 5FU-based chemoradi-
ation and other cytotoxic agents (mitomycin C) have been established as the standard of care, leading to
complete tumour regression in 80–90% of patients with locoregional failures in the region of 15%. There is
an accepted role for surgical salvage. Assessment and treatment should be carried out in specialised
centres treating a high number of patients as early as possible in the clinical diagnosis. To date, the
limited evidence from only 6 randomised trials [1,2,3,4,5,6,7], the rarity of the cancer, and the different
behaviour/natural history depending on the predominant site of origin, (the anal margin, anal canal or
above the dentate line) provide scanty direction for any individual oncologist. Here we aim to provide
guidelines which can assist medical, radiation and surgical oncologists in the practical management of
this unusual cancer.
 2014 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 111 (2014) 330–339
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/3.0/).Aetiology
Squamous cell carcinoma of the anus (SCCA) is strongly associ-
ated with human papillomavirus (HPV) infection which represents
the causative agent in 80–85% of patients (usually from HPV16
or HPV18 subtypes in Europe) as is its precursor lesion AnalIntraepithelial Neoplasia (AIN) 3. Factors increasing the risk of
HPV infection and/or modulating host response and the persis-
tence of this infection appear to affect the epidemiology of this
tumour. Anal intercourse and a high lifetime number of sexual
partners increase the risk of persistent HPV infection in men
and women, leading eventually to malignancy. Other important
risk factors include human immunodeﬁciency virus (HIV), immune
suppression in transplant recipients, use of immunosuppressants
such as long-term corticosteroids, a history of other HPV-related
cancers, autoimmune disorders, social deprivation and cigarette
smoking. Cigarette smoking may also be important in the
modulation/persistence of HPV infection and, hence, outcomes
from treatment. Herpes simplex virus (HSV) may play a secondary
role in disease progression. Dietary habits, chronic inﬂammatory
diseases and the presence of haemorrhoids do not appear to pre-
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men (MSM), the incidence of anal cancer is in the region of 35 per
100,000. In men who are HIV seropositive, the incidence increases
to 75–135 per 100,000. The incidence is also higher among HIV
seropositive women. Prolonged survival with Highly Active Anti
Retroviral Treatment (HAART) is likely to lead to further increase
in incidence among HIV positive subjects.Incidence and epidemiology
Epidermoid anal cancer is a rare disease accounting for 1–2% of
digestive tract tumours and 2–4% of colon, rectal and anal tumours.
The annual incidence is 1 in 100,000, is higher in women and is
increasing [1]. In Europe, approximately 2000 males and 2300
females are diagnosed with anal cancer every year. Five-year
survival has changed little in the last two decades. In the US, the
overall 5-year survival rates for 1994–2000 were 60% for men
and 78% for women (SEER data). In Europe 5-year survival varied
between 66% (Central Europe) and 44% (Eastern Europe).Diagnosis
SCCA commonly presents with bleeding; hence, diagnosis is
often delayed because bleeding is attributed to haemorrhoids.
SCCA may also present with any combination of a mass, non-healing
ulcer, pain, bleeding, itching, discharge, faecal incontinence, and
ﬁstulae. Not uncommonly lesions are palpated ﬁrst by the patient.
The diagnosis of anal cancer is made on biopsy-proven histology.
Small, early cancers are sometimes diagnosed serendipitously
following the removal of anal tags. More advanced lesions in the
distal anal canal may extend onto the skin at the anal margin.
Rarely patients present with inguinal lymphadenopathy.Screening and prevention
The existence of an identiﬁed viral aetiological agent and the
ability to detect preneoplastic lesions may allow the development
of screening and prevention programmes. Vaccination of girls
against oncogenic HPV is now being recommended for the preven-
tion of cervical cancer, and a recent report indicated that up to 80%
of anal cancers could also be avoided with prophylactic quadriva-
lent HPV vaccine (against HPV types 6, 11, 16, and 18). But cur-
rently vaccination has no role when SCCA is actually present [2].
Screening programs using anal cytology and high-resolution
anoscopy have been proposed for high-risk populations (MSM
and HIV – women with a history of anal intercourse or other
HPV-related anogenital malignancies) based on the achievements
obtained in cervical cytology screening. However, no randomised
control study has yet demonstrated the advantage of screening in
these high-risk populations.Pathology/molecular biology
Anal intraepithelial neoplasia
Anal cancer may arise from a precursor dysplastic lesion – AIN,
– also known as anal squamous intraepithelial lesions (SILs). The
prevalence of AIN in the general population is low, but higher in
30–40% of MSMs. Progression from AIN 1 and AIN 2 to AIN 3 is
uncommon, as is progression from AIN 3 to invasive malignancy
in immunocompetent patients, but appears more likely in immu-
nosuppressed patients, and is inﬂuenced by HIV seropositivity,
low CD4 count and serotype of HPV infection.
HPV-associated tumours usually retain wild-type P53, and this
explains why patients with HPV-associated tumours respond wellto concurrent chemoradiotherapy. Data on the interaction with
wild-type P53 in current or former cigarette smokers, as in head
and neck cancer, are lacking.
Both synchronous and metachronous HPV-related vaginal and
cervical intra-epithelial and malignant squamous lesions are
frequent and should be screened for in younger women.Histology
Histological conﬁrmation is mandatory as other histologies are
possible including adenocarcinoma, melanoma, gastrointestinal
stromal tumours, poorly differentiated neuroendocrine tumours,
and lymphoma.
Tumours of the anal margin are generally well-differentiated
and often occur in men, in contrast to canal tumours which are
normally poorly differentiated and more common in women.
Histological grading is subject to inter-observer variability, and
considerable heterogeneity is seen in larger tumours. High-grade
tumours have been thought to have a worse prognosis, but this
has not been conﬁrmed in multivariate analysis. Histological sub-
classiﬁcations of basaloid, transitional, spheroidal and cloacogenic
cell cancers have no additional conﬁrmed bearing on management.
Some authors report that a basaloid histological subtype has a
higher risk of developing metastatic disease. The biology and prog-
nosis of keratinising and non-keratinising tumours of the anal
canal also appear to be similar. Verrucous carcinomas are a variant
and are sometimes described as giant condylomas or Buschke–
Lowenstein tumours, which may have a better prognosis than
SCCA, for whom some consider surgery the best option.Anatomy and lymphatic drainage
Lymph node involvement at diagnosis is observed in 30–40% of
cases while systemic spread is uncommon with distant extrapelvic
metastases recorded in 5–8% at onset.
The anal canal extends from the anorectal junction to the anal
margin (see Fig. 1).
Useful palpable landmarks are the puborectal sling and the
intersphincteric groove, respectively. The columnar, or cylindric,
epithelium of the rectum extends to about 1 cm above the dentate
line where the anal transitional zone begins. Below the dentate line
the epithelium is all squamous. The anal margin is the pigmented
skin immediately surrounding the anal oriﬁce, extending laterally
to a radius of approximately 5 cm. In practice, at diagnosis the pre-
cise point of origin is often uncertain, and the distinction between
anal canal and anal margin tumour is often difﬁcult, if not impos-
sible. Hence, some have classiﬁed into 3 distinct regions – i.e. intra-
anal, perianal (visualised with gentle traction on the buttocks), and
skin tumours (beyond a 5 cm radius from the anal opening).
Proximally lymphatic drainage is to perirectal nodes along the
inferior mesenteric artery. Immediately above the dentate line
drainage is to internal pudendal nodes, and to the internal iliac sys-
tem. Infra-dentate and perianal skin drains to the inguinal, femoral
and external iliac nodes.Clinical assessment
A relevant history is required to elicit symptoms, other relevant
medical conditions, current medications and predisposing factors,
which should be documented. Examination should include digital
rectal examination (DRE) to examine the anal lesion and perirectal
nodal involvement, and in women (particularly with low anteriorly
placed tumours) a vaginal examination to determine the site and
size of the primary tumour, vaginal/vaginal septal involvement,
mucosal involvement and exophytic or ulcerative tumour, or the
Fig. 1. Anatomy of the anal region.
332 Clinical practice guidelinespresence of a ﬁstula (Table 3). Vaginal involvement may require
the prophylatic siting of a defunctioning stoma because of the risk
of an anorectal-vaginal ﬁstula. However, since only 50% of initial
colostomies are reversed, this decision should be weighed care-
fully. Palpation of the inguinal nodes is important, particularly
those superﬁcial inguinal nodes, medial and close to the pubis.
Proctoscopy by a specialist surgeon or radiation oncologist and,
if painful, examination under anaesthesia (EUA) may be appropri-
ate to facilitate biopsy. It is also easier to determine anatomical
relations to surrounding structures and to allow accurate clinical
staging. It is advantageous if the treating radiation oncologist is
present during this EUA to document precise measurements, as
these are often critical for later target volume delineation in
treatment planning.
Colonoscopy is not required to assess pathology in the proximal
bowel, because synchronous lesions are not reported for SCCA.Staging
With an indolent natural history and a low rate of distant
metastases, anal cancer is usually amenable to loco-regional
treatment.
Imaging should include magnetic resonance imaging (MRI) of
the pelvis or, if not available, endo-anal ultrasound (EUS). Distant
metastases can be assessed with computed tomography (CT) of
the thorax and abdomen. MRI provides excellent contrast and
spatial resolution, providing information on tumour size, local
extent and spread, and invasion of adjacent organs and more
accurate nodal involvement [3].
Accurate assessment of tumour size and depth of mural inva-
sion is possible with EUS, due to excellent spatial detail but is best
reserved for small T1 lesions as the small ﬁeld-of-view limits
assessment of regional lymph nodes and inﬁltration of structures
beyond the anal canal.
Positron emission tomography (PET)/CT with [18F] ﬂuorodeoxy-
glucose (FDG-PET/CT) has a high sensitivity in identifying involved
lymph nodes, as the majority of anal carcinomas are FDG-avid.
Several studies have shown that FDG PET/CT can alter staging in
approximately 20% of cases, with a trend towards upstaging, and
can alter treatment intent in approximately 3–5% of cases. The
main impact of FDG PET/CT on therapy stems from its high
sensitivity in identifying involved lymph nodes and inﬂuencing
radiation therapy planning by deﬁning sites of metabolically
active tumour. Therefore, FDG PET has been recommended in thecurrent USA National Comprehensive Cancer Network treatment
recommendations.
The TNM clinical staging system is based on accurate assess-
ment of size (T-stage), regional lymph node involvement (N) and
metastatic spread (M). Nodal status is based on the distance from
the primary site rather than the number of nodes involved – see
Table 1. Nodal involvement of anal canal lesions differs from that
of anal margin tumours.
Biopsy by needle aspiration biopsy is usually only performed for
clinically palpable inguinal nodes or those enlarged greater than
10 mm on CT or MRI. Sentinel lymph node biopsy (SLNB) can reveal
micrometastatic spread of disease, and may be more accurate than
diagnostic imaging, but has not been properly evaluated.
Squamous cell carcinoma antigen (SCCAg) is a serum tumour
marker expressed by carcinomas of the anal canal, and may be
related to tumour stage and/or nodal status, but its clinical utility
in diagnosis and follow-up remains controversial.Risk assessment
Anal cancers occur rarely, and factors inﬂuencing outcome and
long-term survival have proved difﬁcult to study with multivariate
analysis. Several factors are relevant to initial decision making
(Table 2). The European Organisation for Research and Treatment
of Cancer (EORTC)-22861 study demonstrated that skin ulceration,
nodal involvement, and male sex were independent variables asso-
ciated with locoregional failure rate (LRF) and overall survival (OS)
[4]. The Radiation Therapy Oncology Group (RTOG) 9811 analysis
supported the EORTC previously reported factors (clinically
involved nodes and male sex), and also established tumour diam-
eter >5 cm as an independent variable predicting disease-free sur-
vival (DFS) and OS. The ACT I analysis showed that palpable
inguinal nodal status and gender are independently prognostic
for OS, LRF and anal cancer death (ACD). In addition, after adjusting
for sex and nodal status, presenting haemoglobin was a further
prognostic factor for ACD. HIV testing is recommended in any
patient with a lifestyle that puts them at risk of contracting HIV
infections. Some argue that all patients with anal cancer should
be screened for HIV [5].
Prior to the widespread use of HAART, HIV-positive patients
were considered to have enhanced toxicity from chemoradiation
(CRT), particularly in patients with low CD4 counts <200/mm3
which may impact on compliance [6]. Such patients were excluded
from the randomised trials. More recent evidence suggests similar
outcomes in HIV-positive patients treated with HAART in terms of
complete response and survival to HIV-negative patients [7,8].
However, we have no randomised data to guide best practice in
immuno-compromised and HIV-positive patients.
Every effort should be made to ensure patients stop smoking
before therapy, because smoking may worsen acute toxicity during
treatment and enhance late toxicity.Initial management of local and locoregional disease
The primary aim of treatment is to achieve cure with loco-
regional control and preservation of anal function, with the best
possible quality of life. Treatment dramatically differs from adeno-
carcinomas of the lower rectum.
Combinations of 5-Fluorouracil (5FU)-based CRT and other
cytotoxic agents (mainly mitomycin C [MMC]) have been
established as the standard of care, leading to complete tumour
regression in 80–90% of patients, with locoregional failures
of about 15%. A multidisciplinary approach is mandatory, involv-
ing radiation therapists, medical oncologists, surgeons, radiologists
and pathologists. The role of surgery as a salvage treatment is
Table 1
TNM staging. American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) seventh edition TNM clinical and pathological classiﬁcation of anal cancer.
Primary tumour (T)
TX Primary tumour cannot be assessed
T0 No evidence of primary tumour
Tis Carcinoma in situ (i.e., Bowen disease, high-grade squamous intraepithelial lesion, and anal intraepithelial neoplasia II–III)
T1 Tumour 62 cm in greatest dimension
T2 Tumour >2 cm but 65 cm in greatest dimension
T3 Tumour >5 cm in greatest dimension
T4 Tumour of any size invades adjacent organ(s), e.g., vagina, urethra, and bladder.
Regional lymph nodes (N)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastases in perirectal lymph node(s)
N2 Metastases in unilateral internal iliac and/or inguinal lymph node(s)
N3 Metastases in perirectal and inguinal lymph nodes and/or bilateral internal iliac and/or inguinal lymph nodes
Distant metastasis (M)
M0 No distant metastasis
M1 Distant metastasis
Anatomic stage/prognostic groups
Stage T N M
0 Tis N0 M0
I T1 N0 M0
II T2 N0 M0
T3 N0 M0




IIIB T4 N1 M0
Any T N2 M0
Any T N3 M0
IV Any T Any N M1
In: Edge SB, Byrd DR, Compton CC, editors. AJCC cancer staging handbook, 7th ed. New York, NY: Springer; 2010. Used with the permission of the American Joint Committee
on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC cancer staging handbook, Seventh Edition (2010) published by Springer Science and
Business Media LLC, www.springer.com.
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lised centres treating a high number of patients as early as possible
in the clinical diagnosis. To date, the limited evidence from only 6
randomised trials [4,9,10,11,12,13], the rarity of the cancer, and the
different behaviour/natural history depending on the predominant
site of origin, (the anal margin, anal canal or above the dentate line)
provide limited direction for any individual oncologist (Table 4). An
example of treatment of anal cancer is shown in Fig. 2.Surgery as primary treatment
Until the mid-1980s, radical surgery was the cornerstone of
treatment. However, following publications from the 1970s on
combined modality therapy, surgery as the primary therapeutic
option has generally been abandoned.
Still today, smaller lesions (<2 cm in diameter), involving the
anal margin and not poorly differentiated may be treated by
primary surgery in the form of a local excision provided adequate
margins (>5 mm) can be obtained without compromising
sphincter function [IV, C]. Local excision has not been shown to
be efﬁcacious for small tumours in the anal canal and is contra-
indicated. Although more extensive and poorly differentiated
lesions have a greater risk of being lymph node positive, it is
important to do proper clinical and radiological staging also of
smaller lesions in order to rule out the presence of positive nodes
as this is a contra indication to local excision. Piece-meal resections
render assessment of resection margins in the specimen impossi-
ble and should not be performed.
In case of inadequate margins or R1-resection (occurs some-
times after a resection of ‘‘anal tags’’ or ‘‘haemorrhoids’’) a furtherlocal excision may be considered after adequate staging, and clin-
ical assessment provided R0-resection can be achieved. However, it
is recommended that all patients having undergone a local resec-
tion, irrespective of resection margin, should be discussed by an
appropriate multidisciplinary team (MDT) to facilitate decisions
regarding re-excision or deﬁnitive CRT.
Until the introduction of deﬁnitive CRT, abdominoperineal exci-
sion (APE) was recommended for all other tumours (except those
amenable to local excision). Primary APE was associated with local
failure in up to half of cases, and 5-year survival rates in the region
of 50–70% were reported [IV, C]. Today, primary APE may be
offered to patients previously irradiated in the pelvic region.Chemoradiation (CRT)
Evidence supporting the effectiveness of CRT as a radical treat-
ment has been provided by multiple phase II and case-series stud-
ies. Subsequent randomised trials have established the optimal
regimen, although no individual randomised study has directly
compared surgery versus CRT. Recommendations are based on the
results of the phase II and six randomised phase III trials (EORTC
22861, UKCCCR ACT I, RTOG 87-04, RTOG 98-11, ACCORD-03, CRUK
ACT II). 5FU with MMC combined with radiotherapy are generally
recommended, rather than 5FU and cisplatin, MMC and cisplatin,
any single drug or any combination of three drugs [I, A].
Stage I patients represent only 10–15% in the majority of ran-
domised CRT trials, hence application of overall data to T1 tumours
is limited. However, for small tumours (T1), some investigators have
used external beam radiotherapy alone, followed by a small volume
boost either with photons, electrons or interstitial implantation.
Table 2
Factors to consider in treatment decision-making for anal cancer.
Disease-related factors Patient-related factors Other
Clinical and radiological TNM stage Patient preferences Local expertise (brachytherapy etc.)
Site of tumour (margin, canal, rectal) Biological age/renal function/Charlson geriatric assessment Geriatricians with interest in oncology
Extent of tumour i.e. involvement of vagina
(risk of ﬁstulation) in addition to size
Co-morbidities/current medications and performance status
Response to treatment (early and at 26 weeks) Socio-economic and psychological factors/social support
Need for symptom control Severity of initial symptoms Specialist palliative care
334 Clinical practice guidelinesIn contrast, early investigators [15,16] reported that CRT, with
the addition of MMC to 5FU, demonstrated excellent local control
in small tumours (<4 cm). Sequential phase II studies with CRT
have shown the efﬁcacy of relatively low total radiation doses
(30–50 Gy) in combination with 5FU and MMC.
Randomised controlled studies in Europe have demonstrated
that synchronous CRT, as the primary modality, is superior to
radiotherapy alone. The RTOG phase III study compared 5FU with
5FU and MMC in combination with radiotherapy (median dose
48 Gy), and did not use a planned gap, but boosted poor responders
with a further 9 Gy. This study conﬁrmed the superiority of the
combination of MMC and 5FU.
It remains unclear whether increasing the radiation dose to
>50 Gy in patients with locally advanced anal cancer receiving
combined modality therapy will improve the results – particularly
in good responders.
The second generation of randomised studies investigated the
role of cisplatin as a replacement of MMC in combination with
5FU and radiation. In these studies, cisplatin and FU were also used
before or after chemoradiaton as neoadjuvant or maintenance
treatment respectively.
The results of these studies indicate that
(1) Cisplatin in combination with infused 5FU and radiation
does not improve either complete response rates or local
control compared with MMC and does not reduce overall
toxicity (but results in less myelotoxicity).
(2) Neoadjuvant chemotherapy before CRT has not improved
either loco-regional or distant control, and colostomy-free
survival (CFS) is signiﬁcantly worse [4,9,11]. More matureFig. 2. Chemoradiation schedule used as a control arm in the ACT II trial as a working
should not be considered standard of care.data suggest that local control and DFS are also worse [11].
Neoadjuvant chemotherapy should not be given outside
clinical trials [I].
(3) Additional maintenance/consolidation chemotherapy fol-
lowing CRT has not impacted on local control, DFS or OS
[10].
The 2 months treatment gap used in early trials, which aimed to
allow time for tumour shrinkage and recovery of acute pelvic tox-
icity has now been abandoned (consensus of experts).
Although randomised trials have not been performed, the
evidence from phase II studies and data extrapolated from ran-
domised trials in rectal cancer suggest that capecitabine might
be considered as an alternative to infused 5FU.Radiotherapy technique and treatment ﬁelds
The patient is usually treated in the supine position, although
there are some exceptions where prone positioning for very exo-
phytic tumours may be better with bolus applied.
Uninterrupted treatment, avoiding a gap, is considered radiobi-
ologically the most effective treatment [III]. Doses of at least
45–50 Gy without a treatment gap are recommended for T1–2
N0. Higher doses may be required for more advanced tumours,
particularly if a planned treatment gap is used. Boost doses to
the primary tumour have usually ranged from 15 to 25 Gy, with
higher doses applied for observed poor response. Hence, currently
it is not possible to make a deﬁnitive recommendation (based on
inter-trial comparisons of differing dose fractionations with orexample of treatment for anal cancer. ⁄Please note that the radiotherapy schedule
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nal beam or brachytherapy) or the appropriate doses for a boost
after 50 Gy.
Dogmatic deﬁnition of treatment ﬁelds is also beyond the scope
of this article. There are signiﬁcant differences in approach within
Europe but, in general, treatment should aim to encompass the
primary tumour and any sites of likely nodal involvement within
the high-dose volume.
Delivery of radiotherapy in anal cancer is complex because of
the varying size and shape of the target volume, and the proximity
to dose-sensitive critical structures, such as small bowel, rectum,
bladder femoral heads, perineum, and external genitalia. These
structures often received high doses of radiation with conventional
parallel opposed techniques. The ﬁrst randomised trials have
mainly relied on two-dimensional (2D)-based radiation therapy
planning in which anatomic (bony) landmarks were used to guide
ﬁeld design using orthogonal X-ray images. More recently, confor-
mal (CT-guided or three-dimensional [3D]) radiotherapy-based
treatments have been used, which allow the radiation oncologist
to identify normal as well as target soft-tissue structures on axial
CT images, and have led to improved treatment accuracy and
delivery.
Recent randomised trials [4,10,11] have shown good local con-
trol in early stage tumours. However, radiotherapy techniques that
have relied on anterior–posterior/posterior–anterior (APPA) ﬁelds
may be associated with severe acute toxicity causing excessive
breaks in treatment leading to treatment failure, and also late
radiation morbidity.
Overall Grade 3 and 4 acute toxicity during CRT in ACT II and
RTOG 9811 was similar in both arms i.e. 72% and 74%, respectively.
The most common Grade 3/4 adverse events were; skin, haemato-
logical, and gastrointestinal [4,10]. More conformal treatment
strategies such as intensity modulated radiotherapy (IMRT) spare
organs at risk, reduce toxicity, and may allow full or even escalated
doses to be achieved within a shorter overall treatment time (OTT).
Hence IMRT or volumetric modulated arc therapy (VMAT) are
currently recommended for the treatment of anal cancer setting
strict radiation dose constraints to normal organs.
Several ‘proof of principle’ studies of IMRT in anal canal carci-
noma have reported signiﬁcant reduction in the doses delivered
to the bowel, bladder and genitalia/perineal skin. Prospective
phase II multicentre studies (RTOG 0529) have shown that IMRT
is deliverable in a multicentre setting [17,18], with a reduction in
toxicity when contrasted with the best arm of the RTOG 9811 trial.
The efﬁcacy of doses less than 1.8 Gy per day are assumed, but data
are inadequate.
Australasian planning guidelines interpret CT deﬁnitions and
provide a high-resolution atlas for contouring gross disease and
organs at risk [19], which complements the existing RTOG elective
nodal ano-rectal atlas [20]. The descriptions of the elective target
volumes or compartments are useful and reproducible.Table 3
Diagnostic work-up.
Mandatory Optiona
Biopsy to conﬁrm diagnosis
Full medical history HIV tes
Full clinical body exam Needle
Digital rectal examination Examin




Assessment of genital tract in females for CIN/VIN
CIN, cervical intraepithelial neoplasia; VIN, vulval intraepithelial neoplasia; MRI, ma
tomography; PET, positron emission tomography.The inguinal nodes should be formally included in the radiation
ﬁelds in the majority of cases, even in the absence of clearly
demonstrable involvement. The incidence of nodal involvement
increases with increasing primary tumour size and is at least 20%
in patients with T3 disease. However, some clinicians may treat
clinically uninvolved inguinal nodes only in certain circumstances
(e.g. T3–4 primary disease, location of primary tumour within the
canal (below the dentate line), 61 cm from the anal oriﬁce or if
there is involvement of pelvic lymph nodes (on CT or MRI criteria).Brachytherapy
Brachytherapy is a highly conformal treatment which is able to
deliver a high dose to the primary tumour, sparing surrounding
normal tissues and the contralateral mucosa and sphincter. Exper-
tise for iridium-192 interstitial implantation is limited to a few
European institutions. Low-dose rate, high dose rate (HDR) and
pulsed dose rate brachytherapy have been tested in clinical prac-
tice. There are currently limited data on the use of HDR brachy-
therapy in anal cancer and lack of consensus on the optimal
fractionation schedule. Curative brachytherapy as a single modal-
ity is not recommended, but may be applicable as a boost following
response to CRT. Double-plane, or volume implants may be neces-
sary, depending on the extent of the tumour, but risk late necrosis
and radiation proctitis. Computerised 3-dimensional image-based
treatment planning should allow optimal dose distribution.Treatment of the elderly
Although some have recommended dose reductions, omission
of chemotherapy or reduction of irradiated volumes for elderly
and frail patients, current data suggest that elderly patients should
be treated similarly to their younger counterparts. The physiolog-
ical ﬁtness of elderly patients is increasing with longer predicted
life expectancy (based upon actuarial tables). Consequently this
group of patients are at risk of signiﬁcant under-treatment if treat-
ment choices are based purely upon age. A good collaboration
between geriatricians, clinical nurse specialists and radiation and
medical oncologists will facilitate the delivery of radical treatment.Postoperative chemoradiation
Postoperative CRT should be considered in patients who have
undergone excision of perianal skin tags where piecemeal histolog-
ical assessment means that completeness of excision cannot be
guaranteed, or in the case of narrow margins, when re-excision is
not feasible, and for patients considered at risk of pelvic node
involvement. Similar indications as for skin cancers are relevant
i.e. depth of invasion, size of tumour and the extent of the surgical







gnetic resonance imaging; HIV, human immunodeﬁciency virus; CT, computed
Table 4
Stage and site-based treatment.
Anal canal
Surgery (radical or local excision) generally contraindicated as primary treatment option
STAGE l - Standard dose radiotherapy (RT), infused 5FU and mitomycin (stage group under-represented in randomised studies)
- low dose RT, infused FU and mitomycin (no data from randomised studies)
STAGE ll–lll - Standard dose RT, infused FU and mitomycin (evidence from multiple randomised studies)
STAGE lV - 5-FU and cisplatin, carboplatin/taxol, or possibly irinotecan/cetuximab
Anal margin
STAGE l, well differentiated - Local excision (re-excision or chemoradiation if involved/close margins)
STAGE ll–lll - standard dose RT, infused 5FU and mitomycin C
STAGE lV - 5-FU and cisplatin, or carboplatin/taxol
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surgery has been performed as primary treatment but the resec-
tion margin is involved. It is recommended that all such patients
should be discussed by an appropriate MDT to facilitate decisions
regarding re-excision or postoperative CRT.Toxicity and supportive care during radiotherapy
Patients should be assessed, and full blood counts checked
weekly if MMC is used, as CRT is associated with high risks of
higher grades of haematological toxicity. Patients should be
informed of the negative effect of smoking before CRT. Smoking
may worsen acute toxicity during treatment and lead to a poorer
outcome in terms of DFS and CFS. Every effort should be made to
ensure patients quit smoking before therapy.
Tolerance to treatment can be maximised with antibiotics, anti-
fungals, anti-emetics, analgesia, skin care, advice regarding nutri-
tion to prevent or correct weight loss, and psychological support.
The recommendation for post-treatment use of vaginal dilators
in sexually active females is controversial. Pre-menopausal women
should be informed that menopause will ensue and fertility will be
lost, unless the ovaries are moved out of the radiation ﬁeld.
Hormone replacement therapy may be appropriate in those in
whom an early menopause is induced. Sperm banking should be
discussed before the commencement of treatment with male
patients who wish to preserve fertility.Response evaluation
Anal cancers tend to regress slowly after completion of CRT
treatment. DRE is the mainstay of determining complete response
after treatment – deﬁned as the absence of tumour and/or ulcera-
tion. Examination may be more informative when performed
under general anaesthesia if pain persists or response is difﬁcult
to quantify. Careful clinical inspection of the inguinal regions in
addition to radiographic evaluation (with pelvic MRI and CT scans,
or as a comparison of PET–CTs, if available) is also necessary.
Oedema, residual ﬁbrosis or scar tissue can be difﬁcult to distin-
guish from persistent active disease. However, biopsies of persis-
tent clinically suspicious lesions 8–12 weeks after CRT
completion are not routinely recommended. Treatment-related
effects may confound the pathological interpretation of post-
treatment biopsies. Good radiographic partial regression can be
managed by close follow-up, to conﬁrm that (a delayed) complete
regression takes place, which may take 6 months. A decision
regarding salvage surgery should be deferred safely in these cir-
cumstances. Hazard ratios from the ACT II data indicate that
assessment at 26 weeks is the most discriminating endpoint with
the most signiﬁcant effect on outcome, and is therefore the opti-
mum time point for deﬁnitive assessment with a view to salvagesurgery. Residual or ‘recurrent’ tumour must be conﬁrmed histo-
logically before considering proceeding to radical surgery.
MRI complements clinical assessment, and acts as a useful base-
line. MRI can capture and document response, but no individual
MRI feature appears predictive of eventual outcome [14]. EUS is
controversial as oedema and scar tissue may be difﬁcult to
distinguish from persistent tumour.
To date few FDG PET/CT studies have assessed treatment
response, and the timing of assessment is controversial. The
beneﬁt of PET is rather to detect residual subclinical pelvic or
extrapelvic/para-aortic node involvement.
Prognostic factors
Prognostic factors for survival (and CFS) in anal cancer include
male sex, positive lymph nodes particularly positive inguinal
lymph nodes and primary tumour size >5 cm. The original EORTC
22861 trial also found that skin ulceration was prognostic for
worse survival and local control. Recent multivariate analysis from
the ACT I trial validated against the ACT II data set showed that
positive inguinal nodes and the male sex were prognostic for local
regional failure, ACD and OS, as was haemoglobin [21]. Even in the
context of HIV, patients with anal cancer who smoke also appear to
have a worse OS than non-smokers.
Personalised medicine
Despite intriguing developments in our understanding of the
molecular biology and processes which lead to anal cancer, there
remains considerable heterogeneity in terms of outcomes, particu-
larly for more advanced stages. Biomarkers to provide predictive
and prognostic information, and inform individualised therapies
would be helpful. Only a limited number of markers in small
numbers have been analysed to date, with a variety of treatment
regimens. Cytogenetic, immunohistochernical and molecular
markers provide information on cancer pathogenesis, but are not
sufﬁciently robust to guide prognosis or select treatment. Further
work in the randomised studies is required.
The cell cycle regulator, p16 is overexpressed in high-risk-HPV-
related cervical cancers, which may represent a simple surrogate
biomarker for identifying squamous cell carcinomas harbouring
HPV DNA. Patients with moderate/strong p16 staining may achieve
better response to CRT and have a lower risk of relapse than
patients with absent or weak staining.
A recent systematic review examined 29 different biomarkers
[22]. Tumour-suppressor genes p53 and p21 were the only bio-
markers which were prognostic in more than one study. Molecular
biomarkers associated with HPV deregulation (i.e. p16, Ki67,
MCM7, K17, K7, K2, and HPV E4) may be relevant. In an analysis
of 240 patients randomised in the UKCCR ACT I anal cancer trial,
the presence of mutated p53 predicted for a poorer cause-speciﬁc
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sistently predict sensitivity to chemoradiation, and more research
is required to identify molecular markers.Follow-up and surveillance and long-term implications
Follow-up
Patients in complete remission at 8 weeks should be evaluated
every 3–6 months for a period of 2 years, and 6–12 monthly
until 5 years, with clinical examination including DRE and palpa-
tion of the inguinal lymph nodes. Anoscopy or proctoscopy is an
additional option, but is sometimes poorly tolerated and too
painful following CRT. Some recommend MRI on a 6 monthly basis
for 3 years. Suspicious progressing lesions should be biopsied. Data
from ACT II suggest very few (<1%) relapses occur after 3 years, so
extended imaging surveillance after this time is not recommended.
Patients tend to relapse loco-regionally rather than at distant
sites. Regular CT scans for metastatic surveillance outside trials
remains controversial, as the evidence for beneﬁt of resection of
metastases as performed in colorectal cancer is lacking, although
anecdotally, salvage is achieved in some cases.Management of advanced/metastatic disease
Approximately 10–20% of patients suffer distant relapse. The
most common sites of metastatic spread are to the paraortic nodes,
liver, lungs and skin, which usually appear relatively late and in the
context of local persistence or recurrence of disease following
treatment. The prognosis in this group is poor with only 10% of
patients with distant metastases surviving 2 years or more, but
long-term survivors are described. Patients with small volume or
isolated metastatic disease should be further discussed by an
appropriate MDT in case there are surgical or chemoradiotherapy
options.
There is no consensus on the standard chemotherapy treat-
ment. The choice of chemotherapy is often inﬂuenced by previ-
ously used agents in the initial CRT regimen, but regimens with
good documented activity are limited and generally have produced
unsatisfactory results.
Otherwise ﬁt patients with symptomatic metastatic or recur-
rent disease not amenable to surgery should be considered for
chemotherapy, usually with a combination of cisplatin and 5FU.
Activity is also reported for carboplatin, doxorubicin, taxanes and
irinotecan ± cetuximab – or combinations of these agents. These
options will be inﬂuenced by the disease-free interval, and the
patient’s preferences and performance status. Responses are rarely
complete and usually of short duration. Currently, the interna-
tional rare cancers initiative (IRCI), which is a consortium of
international investigators from the UK, US, Europe and Australia,
has developed a multicentre international trial testing the role
of carboplatin/paclitaxel against the common standard 5-FU/
cisplatin.Quality of life
Data on long-term quality of life are sparse, but appear to show
that patients are satisﬁed despite objective impairment of sphinc-
ter function. Continence and quality of life appear impaired in
many patients [23,24]. Efforts should be made to document quality
of life and late effects. Population data suggest that function is
poor, particularly if patients continue to smoke.
Sexual and urinary function may also be compromised. In the
RTOG 9811 trial, the rate of severe long-term toxic effects was
similar in both arms, 11% versus 10%, but only 5% required a colos-
tomy for treatment-related late effects. Adverse late effects appearto relate mostly to total radiation dose received in multivariate
analysis rather than the type of chemotherapy.
Information regarding treatment side effects should be pro-
vided clearly, particularly on sexual functioning as substantial
numbers of patients describe difﬁculty with their sex lives, with
speciﬁc concerns regarding loss of libido, inability to enjoy sex
and erectile dysfunction. Follow up of issues relating to sexual
dysfunction has been suboptimal, particularly for female patients
who have undergone radical pelvic radiotherapy.
There is increasing support in the literature towards the devel-
opment of nurse-led, late effects/survivorship clinics for patients
who have received pelvic radiotherapy. There are reports detailing
the effectiveness of pelvic ﬂoor exercises and/or biofeedback train-
ing in patients who experience faecal urgency and incontinence.Salvage surgical treatment
Patients with locally persistent, progressive or recurrent disease
should be considered for surgical salvage [I, A]. A very small pro-
portion of patients may be treated by local resection. At least an
abdomino-perineal excision is required in the majority of patients
since achievement of a negative resection margin appears crucial.
For some patients, a posterior or total pelvic exenteration is
required and surgery should preferably be carried out in institu-
tions with experience of multivisceral resections. In addition to a
positive biopsy, preoperative local staging is mandatory and MRI
provides an excellent alternative. Although distant metastases
are unusual, CT scan of thorax and abdomen (or PET/CT) is advised
to rule out the occurrence of such. Because the salvage operation
for anal cancer involves a wider perineal resection than what is
done in rectal cancer, and surgery is performed in a heavily irradi-
ated area, the risk of postoperative complications, in particular
involving the perineal wound, are substantial. Perineal reconstruc-
tion with musculocutaneous ﬂaps is generally recommended and
appears to reduce complication rates [25]. Persistent or progressive
disease in the inguinal lymph nodes should be considered for
surgery, i.e. radical groin dissection and pre- or post-operative
irradiation discussed – depending on the dose distribution from
the deﬁnitive CRT. Flap reconstruction may be needed in some
instances when recurrence in an irradiated groin is subject to sur-
gical salvage. Salvage surgery can achieve local pelvic control in
approximately 60% of cases, and a 5-year survival rate of 30–60%.Palliative care
Pain due to recurrent pelvic tumour can be extreme, and
requires expertise in combinations of opiate and non-opiate pain
relief, sedatives, and anxiolytics. Nerve blocks and re-irradiation
may be feasible. Fistula from the bladder or rectum is not uncom-
mon and demands meticulous skin care, and, rarely, surgical diver-
sion procedures in patients with reasonable life-expectancy.
Palliation of the dying patient with anal cancer is often difﬁcult.
The symptoms are often odorous and may make emotional support
for the patient and family members very challenging.
Conclusion
A MDT approach is essential for the optimal management of
anal cancer. Despite the results of four randomised phase III trials
in anal cancer, the paradigm of external beam radiation therapy
with concurrent 5FU and MMC developed over 30 years ago by
Norman Nigro remains the standard of care.
As anal cancer is a rare tumour, the authors strongly believe
that it is in the interest of all patients to be offered participation
in a clinical trial. National and international trials in this disease
site are ongoing throughout Europe.
Table 5
Summary of recommendations.
 Patients with anal cancer should be managed, from diagnosis through initial treatment and subsequent surveillance, by an experienced and specialised multidis-
ciplinary team.
 Loco-regional control with good quality of life and the avoidance of a permanent stoma is the primary aim of treatment.
 The optimal total dose of radiation is unknown. Chemoradiation with at least 45 Gy, infused FU and mitomycin remains the standard treatment for stage II or higher
anal canal tumours and a boost with 15–20 Gy may be applicable, especially if chemotherapy cannot be safely delivered, leading to cure in the majority of patients.
 Less intensive treatment programs with lower doses of irradiation may be successfully used in smaller tumours or fragile patients although evidence from random-
ised trials is not available.
 Neoadjuvant and adjuvant chemotherapy using cisplatin has not been shown to improve outcomes (progression-free survival or OS).
 Chemoradiation with 5FU and cisplatin had similar complete response and overall toxicity when compared with 5FU and MMC but less haematological toxicity.
Any marginal beneﬁt for cisplatin in terms of haematological toxicity is likely to be outweighed by the extra resources needed to administer cisplatin – two courses
of intravenous treatment with hydration over several hours, compared with only a single dose of MMC.
 Response should be assessed from 6 weeks, but data suggest that the optimal time to assess complete response may be 26 weeks, rather than 11 weeks, if surgical
salvage is discussed.
 Surveillance/follow-up after completion of chemoradiation treatment have not been rigorously examined, but should focus on salvage of local failure (less than 10%
will recur after the ﬁrst three years following completion of chemoradiation treatment).
 The techniques for surgical salvage in anal cancer are different to that performed for rectal cancer, are associated with high morbidity, and require input frommulti-
ple surgical teams (e.g. urology and plastic reconstruction).
Table 6
Levels of evidence and grades of recommendation (adapted from the Infectious Diseases Society of America-United States Public Health Service Grading Systema).
Levels of evidence
I Evidence from at least one large randomised, controlled trial of good methodological quality (low potential for bias) or meta-analyses of well-conducted
randomised trials without heterogeneity
II Small randomised trials or large randomised trials with a suspicion of bias (lower methodological quality) or meta-analyses of such trials or of trials with
demonstrated heterogeneity
III Prospective cohort studies
IV Retrospective cohort studies or case-control studies
V Studies without control group, case reports, experts opinions
Grades of recommendation
A Strong evidence for efﬁcacy with a substantial clinical beneﬁt, strongly recommended
B Strong or moderate evidence for efﬁcacy but with a limited clinical beneﬁt, generally recommended
C Insufﬁcient evidence for efﬁcacy or beneﬁt does not outweigh the risk or the disadvantages (adverse events, costs, ...), optional
D Moderate evidence against efﬁcacy or for adverse outcome, generally not recommended
E Strong evidence against efﬁcacy or for adverse outcome, never recommended
a Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139–144.
By permission of the Infectious Diseases Society of America.
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PubMed and Medline were searched for articles published
between 1990 and June 2013. The search terms included squamous
cell carcinoma, anal cancer, anal canal carcinoma, anal margin can-
cer, survival, diagnosis, recurrence, surgery, chemotherapy, radio-
therapy, chemoradiation, chemo-radiotherapy.
Recent reviews and guidelines are available as listed in the
literature.
A summary of recommendations is provided in Table 5. Levels
of evidence and grades of recommendation have been applied
using the system shown in Table 6. Statements without grading
were considered justiﬁed standard clinical practice by the expert
authors and the reviewers. The present guidelines have been
formulated with the assistance of the United Kingdom National
Cancer Research Institute (NCRI) multidisciplinary Anal Cancer
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